Adult Acute Lymphocytic Leukemia Clinical Trial
Official title:
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003)
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for patients with high and very high risk of relapse. Patients with standard risk receive further consolidation and reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. After six months and one year the decision on intensification or discontinuation of therapy is made based on the results of MRD evaluation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00199056 -
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
|
Phase 4 | |
| Completed |
NCT00199043 -
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
|
Phase 3 | |
| Completed |
NCT00198978 -
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
|
Phase 4 | |
| Completed |
NCT00199095 -
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
|
Phase 4 | |
| Completed |
NCT00199004 -
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
|
Phase 4 | |
| Completed |
NCT00199108 -
Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt
|
Phase 2/Phase 3 | |
| Completed |
NCT00199069 -
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
|
Phase 4 |